Evidence map›Paper›PMID 33328255›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2021

Epidemiology and Outcomes of Young-Onset Esophageal Adenocarcinoma: An Analysis from a Population-Based Database.

Don C Codipilly, Tarek Sawas, Lovekirat Dhaliwal, Michele L Johnson, Ramona Lansing, Kenneth K Wang, Cadman L Leggett, David A Katzka, Prasad G Iyer

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Early- versus late-onset gastroesophageal cancer: real-world outcomes from a 13-year central European cohort study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Interactions between cancer-associated fibroblasts and the extracellular matrix in oesophageal cancer.Matrix biology : journal of the International Society for Matrix Biology · 2025
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Don C CodipillyDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Tarek SawasDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Lovekirat DhaliwalDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Michele L JohnsonDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Ramona LansingDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Kenneth K WangDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Cadman L LeggettDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
David A Katzka *Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0003-2307-2317
Prasad G Iyer *Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. iyer.prasad@mayo.edu.

Funding

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
Minimally Invasive Molecular Approaches for the Detection of Barrett’s Esophagus and Esophageal AdenocarcinomaR01CA241164 · NCI · MAYO CLINIC ROCHESTER · PI Jagpreet Chhatwal, Prasad G. Iyer · 2019 to 2026
$3.9M
NCATS NIH HHS UL1 TR002377NCI NIH HHS R01 CA241164
6 · The paper itself

Abstract

backgroundEsophageal adenocarcinoma is a lethal cancer with rising incidence. There are limited data in younger (<50 years) patients with esophageal adenocarcinoma. We aimed to assess time trends in the incidence and outcomes of "young-onset" esophageal adenocarcinoma using a population-based database.

methodsWe queried the Surveillance, Epidemiology, and End Results 9 database to identify patients with esophageal adenocarcinoma between 1975 and 2015. Patients were stratified into three age strata: <50, 50 to 69, and ≥70 years. Staging was stratified as localized, regional, and distant. Trends in incidence, disease stage, and survival were assessed in three periods (1975-89, 1990-99, and 2000-2015). Univariate and multivariate models were created to identify predictors of mortality.

resultsEsophageal adenocarcinoma incidence has increased in patients <50 years of age, with an annual percentage change of 2.9% (95% confidence interval, 1.4%-4.4%) from 1975 to 2015. Young-onset esophageal adenocarcinoma presented at more advanced stages (regional + distant) compared with older patients (84.9% vs. 67.3%;

conclusionsYoung-onset esophageal adenocarcinoma, while uncommon, is rising in incidence. Concerningly, the proportion of advanced disease continues to increase. Young-onset esophageal adenocarcinoma also presents at more advanced stages, resulting in poorer esophageal adenocarcinoma-free survival. IMPACT: Patients with esophageal adenocarcinoma younger than 50 years present at more advanced stages with higher esophageal adenocarcinoma-specific mortality compared with older peers. Current diagnostic and management strategies for young-onset esophageal adenocarcinoma may need to be reevaluated.

Indexed as

AdenocarcinomaAdultAgedAge DistributionAge of OnsetEsophageal NeoplasmsFemaleHumansIncidenceKaplan-Meier EstimateMaleMiddle AgedSEER ProgramSex Distribution

Identifiers

PMID33328255
PMCPMC7855414

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.